<DOC>
	<DOCNO>NCT02598297</DOCNO>
	<brief_summary>Myelofibrosis patient high molecular risk mutation intrinsically aggressive disease increase risk leukemic transformation reduce overall survival . As therapy currently establish subset high molecular risk patient early myelofibrosis , study aim evaluate ruxolitinib patient population .</brief_summary>
	<brief_title>Phase III Study Investigating Efficacy Safety Ruxolitinib Early Myelofibrosis Patients With High Molecular Risk Mutations .</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Confirmed diagnosis MF bone marrow fibrosis least Grade 1 ; irrespective JAK2 mutational status Patients least one mutation one five HMR gene ( ASXL1 , EZH2 , SRSF2 IDH1/2 ) Patients nonpalpable spleen spleen palpable ≤ 5 cm leave costal margin point great splenic protrusion Patients MF7 score ≤ 15 , individual symptom score ≤ 3 ● Patients prior treatment ruxolitinib JAK inhibitor . Other protocoldefined inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ruxolitinib</keyword>
	<keyword>INC424</keyword>
	<keyword>early myelofibrosis</keyword>
	<keyword>High molecular risk mutation</keyword>
	<keyword>HMR</keyword>
</DOC>